| Content Provider |
World Health Organization (WHO)-Global Index Medicus |
| Author |
Cui, Z. Chow, D. S-L Wu, L. Lazar, D. A. Rodrigo, R. Olutoye, O. O. Olutoye, O. A. |
| Description |
Author Affiliation: Cui Z ( Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77030, USA. Electronic address: zcui@uh.edu.); Chow DS ( Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77030, USA.); Wu L ( Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77030, USA.); Lazar DA ( Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA); Rodrigo R ( Department of Obstetrics & Gynecology, Baylor College of Medicine, Houston, TX 77030, USA); Olutoye OO ( Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA); Olutoye OA ( Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA) |
| Abstract |
Dexmedetomidine (DEX; Precedex(®)), approved by the Food and Drug Administration (FDA) in 1999 as a sedative for use in the intensive care unit, is a potent and highly selective 2-adrenoceptor agonist with significant sedative, analgesic and anxiolytic effects. However, the research of DEX use during pregnancy is limited and the impact of DEX on the fetal development is unclear. This article describes a high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay suitable for various biomatrices of plasma, urine and amniotic fluid, as a prerequisite for pharmacokinetic characterization of DEX in the pregnant ewe model. DEX and testosterone (internal standard; IS) were extracted from 200µL of plasma, urine or amniotic fluid with ethyl acetate. The HPLC resolution was achieved on an Agilent ZORBAX SB-CN column with a gradient elution at a flow rate of 0.5mL/min using a mobile phase of 5-100% of acetonitrile with 0.5% formic acid (mobile phase B) in water (mobile phase A). The detection was performed by a triple quadrupole tandem mass spectrometer with positive electrospray ionization. The precursor/product transitions (m/z) in the positive ion mode [M+H](+) were m/z 201.5â95.4 for DEX and m/z 289.2â109.1 for IS. The method was validated in the concentration range of 25 (lower limit of quantification; LLOQ)-5000pg/mL for both maternal and fetal plasma, and of 50 (LLOQ)-5000pg/mL for urine and amniotic fluid, respectively. The intra- and inter-day precision and accuracy were within ±9%. The overall recoveries of DEX were 82.9-87.2%, 85.7-88.4%, 86.2-89.7% and 83.7-88.1% for maternal plasma, urine, fetal plasma and amniotic fluid, respectively. The percentage matrix factors in different biomatrices were less than 120%. Stability studies demonstrated that DEX was stable after three freeze/thaw cycles, in the autosampler tray at 20°C for 24h and during the 3h sample preparation at room temperature. The validated HPLC-MS/MS method has been successfully employed for pharmacokinetic evaluation of DEX in pregnant ewes and fetuses. |
| File Format |
HTM / HTML |
| ISSN |
15700232 |
| Volume Number |
961 |
| e-ISSN |
1873376X |
| Journal |
Journal of Chromatography B |
| Language |
English |
| Publisher |
Elsevier |
| Publisher Date |
2014-06-15 |
| Publisher Place |
Netherlands |
| Access Restriction |
One Nation One Subscription (ONOS) |
| Subject Keyword |
Discipline Analytical Chemistry Amniotic Fluid Chemistry Dexmedetomidine Analysis Animals Chromatography, High Pressure Liquid Methods Blood Pharmacokinetics Urine Female Fetal Blood Models, Animal Pregnancy Reproducibility Of Results Sheep Spectrometry, Mass, Electrospray Ionization Tandem Mass Spectrometry Journal Article |
| Content Type |
Text |
| Resource Type |
Article |
| Subject |
Cell Biology Medicine Analytical Chemistry Clinical Biochemistry Biochemistry |
